Disinfection, Tru-D Technology, Uncategorized

The Power of One

You’ve heard about deadly infectious diseases you can catch while you’re in the hospital such as C. diff, MRSA and VRE. Tru-D SmartUVC is a 5’-foot-5’ UV disinfection robot that kills these pathogens and many others with one placement and one cycle in the room, providing one solution for thorough

Read More
Posted 10.31.17
  • Share

Disinfection, Tru-D Technology, Uncategorized

How Do We Manage “Dose” Requirements for UV Disinfection?

In part 1 of our series on “Humans Managing Disinfectant Dwell Time,” Cathy Campbell, Tru-D’s Director of Program Management, shared a concept of having to manage “dwell time” of disinfectant solutions to effectively kill pathogens.  We might agree it’s difficult to maintain vigilance around “watching the solution dry” or ensuring the

Read More
Posted 06.21.17
  • Share

Industry News, Press, Studies, Tru-D News, Tru-D Technology, Uncategorized, Videos

UNC-TV Releases New Video Featuring Tru-D and the BETR-D Study

The University of North Carolina’s “UNC-TV” has released a new video on the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, the first and only randomized clinical trial on UV disinfection. The study proved that Tru-D could cut transmission of four major superbugs by a cumulative 30% among patients who entered the

Read More
Posted 05.18.17
  • Share

Hospital News, Industry News, Press, Tru-D News, Tru-D Technology, Uncategorized

From Duke Health: UVC Light Helps Hospitals Fight Drug-Resistant Superbugs

From Clinical Practice Today by Duke Health:

Read More
Posted 05.10.17
  • Share

Industry News, Studies, Tru-D News, Tru-D Technology, Uncategorized

BETR-D Study Shows 11% C. diff Reduction

Shield Design with 11% Hospital C. Diff Reduction

The Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study is the first and only randomized clinical trial on UV disinfection. The study’s primary outcome showed that enhanced terminal room disinfection strategies that utilized Tru-D reduced the risk of acquisition and infection by a cumulative 30 percent among patients who entered the

Read More
Posted 04.26.17
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »